1 minute reading time (56 words)

First Utahns Treated in Nationwide FDA-Allowed Clinical Study of Locally Developed Cell Therapy for Chronic Low Back Pain

A clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first Utahns have been treated in its nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More